Q2 FY2026 EarningsQ2 FY26 results beat consensus on earnings but missed significantly on revenue, recording zero revenue vs. an expected $0.88M. Diluted EPS was -$0.09, outperforming the -$0.17 mean consensus due to a substantial 48% YoY reduction in R&D expenses as major Phase 3 readiness activities concluded. The company maintains a liquidity position of $72.1M, bolstered by efficient cost management despite the lack of collaboration revenue this quarter.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Silence Therapeutics(SLN) the EBIT is -13.62 M (+41.1%), Beat estimate;the EPS is -0.27 (+52.63%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B407.29%
----
EBITExceed expectations
-0.01B41.10%
-0.02B30.92%
+0.00B10.18%
EPSMiss expectations
-0.2752.63%
-0.172569.74%
-0.097517.11%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf